Impact of the target volume (prostate alone vs. prostate with seminal vesicles) and fraction dose (1.8 Gy vs. 2.0 Gy) on quality of life changes after external-beam radiotherapy for prostate cancer

Strahlentherapie und Onkologie

Volumn 185, Issue 11, 2009, Pages 724-730

  Pinkawa, Michael ^a   Piroth, Marc D ^a   Fischedick, Karin ^a   Holy, Richard ^a   Klotz, Jens ^a   Nussen, Sandra ^a   Krenkel, Barbara ^a   Eble, Michael J ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Clinical target volume; Fractionation; Prostate neoplasm; Quality of life; Radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; SCORING SYSTEM; SEMINAL VESICLE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; DOSE FRACTIONATION; ERECTILE DYSFUNCTION; FECAL INCONTINENCE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RECTUM; SEMINAL VESICLES; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY INCONTINENCE;

EID: 70449746480     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-009-2008-6     Document Type: Article

References (37)

1. T. Akimoto H. Muramatsu M. Takahashi, et al. 2004 Rectal bleeding after hypofractionated radiotherapy for prostate cancer: correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding Int J Radiat Oncol Biol Phys 60 1033 1039 10.1016/j.ijrobp.2004.07.393 15519772
2. A. Al-Mamgani W.L. van Putten W.D. Heemsbergen, et al. 2008 Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 72 980 988 18495377
3. A. Baccala A.M. Reuther F.J. Bianco, et al. 2007 Complete resection of seminal vesicles at radical prostatectomy results in substantial long-term disease-free survival Urology 69 536 540 10.1016/j.urology.2006.12.013 17382160 (Pubitemid 46428400)
4. M. Bohrer P. Schröder G. Welzel, et al. 2008 Reduced rectal toxicity with ultrasound- based image guided radiotherapy using BAT™ (B-mode acquisition and targeting) for prostate cancer Strahlenther Onkol 184 674 678 10.1007/s00066-008-1837-z 19107349
5. M. Bolla D. Gonzalez P. Warde, et al. 1997 Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 295 300 10.1056/NEJM199707313370502 1:CAS:528:DyaK2sXlsVGgs74%3D 9233866 (Pubitemid 27318990)
6. D.J. Brenner 2004 Fractionation and late rectal toxicity Int J Radiat Oncol Biol Phys 60 1013 1015 15519768
7. H. Elsayed T. Bolling C. Moustakis, et al. 2007 Organ movements and dose exposures in teletherapy of prostate cancer using a rectal balloon Strahlenther Onkol 183 617 624 10.1007/s00066-007-1736-8 17960337 (Pubitemid 350124273)
8. S.J. Feigenberg A.L. Hanlon E.M. Horwitz, et al. 2005 Long-term androgen deprivation increases grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy Int J Radiat Oncol Biol Phys 62 397 405 1:CAS:528:DC%2BD2MXktFGhs7s%3D 15890581
9. C. Fiorino G. Sanguineti C. Cozzarini, et al. 2003 Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer Int J Radiat Oncol Biol Phys 57 953 962 14575825
10. I. Gluck K.A. Vineberg R.K. Ten Haken, et al. 2009 Evaluating the relationship between rectal normal tissue complication probability and the portion of seminal vesicles included in the clinical target volume in intensity-modulated radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 73 334 340 19147014
11. G. Goldner H. Bombosch H. Geinitz, et al. 2009 Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy. First report on 5-year morbidity and biochemical control from a prospective Austrian-German multicenter phase II trial Strahlenther Onkol 185 94 100 10.1007/s00066-009-1970-3 19240995
12. G. Goldner B. Tomicek G. Becker, et al. 2007 Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: results of a prospective multicenter study of 166 patients Int J Radiat Oncol Biol Phys 67 78 83 17189064
13. G. Goldner N. Wachter-Gerstner S. Wachter, et al. 2003 Acute side effects during 3-D-planned confromal radiotherapy of prostate cancer. Difference between patient's self-reported questionnaire and the doctor's report Strahlenther Onkol 179 320 327 10.1007/s00066-003-1029-9 12740659 (Pubitemid 36606023)
14. G.E. Hanks T.F. Pajak A. Porter, et al. 2003 Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group protocol 92-02 J Clin Oncol 21 3972 3978 10.1200/JCO.2003.11.023 1:CAS:528:DC%2BD2cXpsVajsbo%3D 14581419 (Pubitemid 46606211)
15. A. Hille M.K.A. Herrmann T. Kertesz, et al. 2008 Sodium butyrate enemas in the treatment of acute radiation-induced proctitis in patients with prostate cancer and the impact on late proctitis Strahlenther Onkol 184 686 692 10.1007/s00066-008-1896-1 19107351
16. A. Hille N. Tows H. Schmidberger, et al. 2005 A prospective three-dimensional analysis about the impact of differences in the clinical target volume in prostate cancer irradiation on normal-tissue exposure. A potential for increasing the benefit/risk ratio Strahlenther Onkol 181 789 795 10.1007/s00066-005-1452-1 16362789 (Pubitemid 41813705)
17. International Commission on Radiation Units and Measurements (ICRU). Prescribing, recording and reporting photon beam therapy. ICRU report 50. Bethesda: ICRU, 1993:1-8.
18. D.A. Kuban S.L. Tucker L. Dong, et al. 2008 Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 67 74 17765406
19. C.A. Lawton M. DeSilvio M. Roach III, et al. 2007 An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions Int J Radiat Oncol Biol Phys 69 646 655 17531401
20. M.E. Lieberfarb D. Schultz R. Whittington, et al. 2002 Using PSA, biopsy Gleason Score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy Int J Radiat Oncol Biol Phys 53 898 903 12095555
21. W. Lilleby E. Dale D.R. Olsen, et al. 2003 Changes in treatment volume of hormonally treated and untreated cancerous prostate and its impact on rectal dose Acta Oncol 42 10 14 10.1080/0891060310002177 12665325 (Pubitemid 36307879)
22. M.S. Litwin D.P. Luebeck J.M. Henning, et al. 1998 Differences in urologist and patient assessments of health-related quality of life in men with prostate cancer: Results of the CaPSURE database J Urol 159 1988 1992 10.1016/S0022-5347(01)63222-1 1:STN:280:DyaK1c3lvVCmsw%3D%3D 9598504
23. J.M. Michalski K. Winter J.A. Purdy, et al. 2005 Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose level V Int J Radiat Oncol Biol Phys 62 706 713 15936549
24. O. Nairz F. Merz H. Deutschmann, et al. 2008 A strategy for the use of image-guided radiotherapy (IGRT) on linear accelerators and its impact on treatment margins for prostate cancer patients Strahlenther Onkol 184 663 667 10.1007/s00066-008-1874-7 19107347
25. M. Pinkawa B. Asadpour B. Gagel, et al. 2006 Prostate position variability and dose-volume histograms in radiotherapy for prostate cancer with full and empty bladder Int J Radiat Oncol Biol Phys 64 856 861 16243443
26. M. Pinkawa K. Fischedick B. Asadpour, et al. 2006 Low-grade toxicity after conformal radiation therapy for prostate cancer - impact of bladder volume Int J Radiat Oncol Biol Phys 64 835 841 16289911
27. M. Pinkawa K. Fischedick B. Asadpour, et al. 2008 Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 70 83 89 17855010
28. M. Pinkawa M.D. Piroth B. Asadpour, et al. 2009 Neoadjuvant hormonal therapy and external-beam radiotherapy versus external-beam irradiation alone for prostate cancer Strahlenther Onkol 185 101 108 10.1007/s00066-009-1894-y 19240996
29. B. Polat I. Guenther J. Wilbert 2008 Intra-fractional uncertainties in image-guided intensity-modulated radiotherapy (IMRT) of prostate cancer Strahlenther Onkol 184 668 673 10.1007/s00066-008-1875-6 19107348
30. T.E. Schultheiss W.R. Lee M.A. Hunt, et al. 1997 Late GI and GU complications in the treatment of prostate cancer Int J Radiat Oncol Biol Phys 37 3 11 1:STN:280:DyaK2s3gslGkug%3D%3D 9054871
31. R.K. Valicenti K. Winter J.D. Cox, et al. 2003 RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity? Int J Radiat Oncol Biol Phys 57 614 620 1:CAS:528:DC%2BD3sXns12rsbs%3D 14529764
32. van der Kogel AJ. Radiation response and tolerance of normal tissues. In: Steel GG, ed. Basic clinical radiobiology. London: Arnold, 2002:30-41.
33. E. Volz-Sidiropoulou M. Pinkawa K. Fischedick, et al. 2008 Factor analysis of the Expanded Prostate Cancer Index Composite (EPIC) in a patient group after primary (external beam radiotherapy and permanent iodine-125 brachytherapy) and postoperative radiotherapy for prostate cancer Curr Urol 2 122 129 10.1159/000189652
34. J.T. Wei R.L. Dunn M.S. Litwin, et al. 2000 Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer Urology 56 899 905 10.1016/S0090-4295(00)00858-X 1:STN:280:DC%2BD3M7hsFCjtw%3D%3D 11113727
35. E.K. Yeoh R.H. Holloway R.J. Fraser, et al. 2009 Anorectal function after three- versus two-dimensional radiation therapy for carcinoma of the prostata Int J Radiat Oncol Biol Phys 73 46 52 18571336
36. M.J. Zelefsky H. Chan M. Hunt, et al. 2006 Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer J Urol 176 1415 1419 10.1016/j.juro.2006.06.002 16952647 (Pubitemid 44307191)
37. A.L. Zietman M. DeSilvio J.D. Slater, et al. 2005 Comparison of conventional-dose vs. high-dose radiation therapy in clinically localized adenocarcinoma of the prostate JAMA 294 1233 1239 10.1001/jama.294.10.1233 1:CAS:528:DC%2BD2MXpvFKhtLw%3D 16160131 (Pubitemid 41352111)